Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.
ANA, anti-nuclear antibodies
Autoallergy
Autoimmunity
CSU phenotypes
CSU, chronic spontaneous urticaria
Cyclosporine
FceR1, high-affinity receptor for Immunoglobulin E
IL-24, interleukin 24
IgE, immunoglobulin E
Omalizumab
Or-CSU, Omalizumab responsive CSU
Resistant CSU
r-CSU, resistant chronic spontaneous urticarial
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
11
04
2020
revised:
13
07
2020
accepted:
15
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Chronic Spontaneous Urticaria (CSU) is a relatively common immune mediated disease that can be effectively treated nowadays. Nevertheless, for some patients remission cannot be achieved following current treatment recommendations, defined as resistant CSU (r-CSU). Treating r-CSU is challenging, and, currently, there are no recommended interventions. In this real-life study we describe successful therapy of 18 r-CSU patients using an "intensified protocol" of anti-IgE-antibody (omalizumab) concomitantly with an immunosuppressant. We defined the r-CSU phenotype and compared it to omalizumab-responsive CSU (Or-CSU) phenotype. Clinical and serological data of 72 CSU patients (ie, 18 r-CSU and 54 age and sex matched Or-CSU) were retrospectively collected and analyzed. All patients were diagnosed with CSU for ≥6 months and treated at the Sheba Medical Center during 2013-2018. Of 289 CSU patients, 18 (6%) were diagnosed with r-CSU and treated with the "intensified protocol" including omalizumab and cyclosporine-A (16p), methotrexate (1p), and azathioprine (1p). Of which, 14/18 (78%) achieved complete remission, 2/18 (11%) partial remission, and 2/18 (11%) no remission. During follow-up no serious adverse events were documented. r-CSU patients received higher doses of antihistamine (p < 0.0001) and omalizumab (425 ± 58 mg/month vs. 283 ± 86 mg/month; p < 0.0001) compared to Or-CSU. The r-CSU phenotype was linked with concomitant autoimmunity (p = 0.0005) and a lower level of IgE prior to initiation of therapy (p = 0.027). r-CSU may be a distinct CSU phenotype characterized by severe disease, concomitant autoimmunity, and lower baseline-IgE levels (low "autoallergy"). An "intensified protocol" with omalizumab and an immunosuppressive agent was found to be efficacious and safe for r-CSU. Further larger studies are required to verify these results.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic Spontaneous Urticaria (CSU) is a relatively common immune mediated disease that can be effectively treated nowadays. Nevertheless, for some patients remission cannot be achieved following current treatment recommendations, defined as resistant CSU (r-CSU). Treating r-CSU is challenging, and, currently, there are no recommended interventions. In this real-life study we describe successful therapy of 18 r-CSU patients using an "intensified protocol" of anti-IgE-antibody (omalizumab) concomitantly with an immunosuppressant. We defined the r-CSU phenotype and compared it to omalizumab-responsive CSU (Or-CSU) phenotype.
METHODS
METHODS
Clinical and serological data of 72 CSU patients (ie, 18 r-CSU and 54 age and sex matched Or-CSU) were retrospectively collected and analyzed. All patients were diagnosed with CSU for ≥6 months and treated at the Sheba Medical Center during 2013-2018.
RESULTS
RESULTS
Of 289 CSU patients, 18 (6%) were diagnosed with r-CSU and treated with the "intensified protocol" including omalizumab and cyclosporine-A (16p), methotrexate (1p), and azathioprine (1p). Of which, 14/18 (78%) achieved complete remission, 2/18 (11%) partial remission, and 2/18 (11%) no remission. During follow-up no serious adverse events were documented. r-CSU patients received higher doses of antihistamine (p < 0.0001) and omalizumab (425 ± 58 mg/month vs. 283 ± 86 mg/month; p < 0.0001) compared to Or-CSU. The r-CSU phenotype was linked with concomitant autoimmunity (p = 0.0005) and a lower level of IgE prior to initiation of therapy (p = 0.027).
CONCLUSION
CONCLUSIONS
r-CSU may be a distinct CSU phenotype characterized by severe disease, concomitant autoimmunity, and lower baseline-IgE levels (low "autoallergy"). An "intensified protocol" with omalizumab and an immunosuppressive agent was found to be efficacious and safe for r-CSU. Further larger studies are required to verify these results.
Identifiants
pubmed: 32774663
doi: 10.1016/j.waojou.2020.100448
pii: S1939-4551(20)30351-3
pii: 100448
pmc: PMC7403771
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100448Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors have nothing to declare.
Références
J Allergy Clin Immunol. 2016 Feb;137(2):474-81
pubmed: 26483177
Am J Med Sci. 2010 Jun;339(6):504-8
pubmed: 20400886
Allergy Asthma Proc. 2015 Mar-Apr;36(2):138-44
pubmed: 25715242
Allergy. 2009 Sep;64(9):1256-68
pubmed: 19650847
Allergy Asthma Immunol Res. 2017 May;9(3):212-219
pubmed: 28293927
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
J Invest Dermatol. 2015 Dec;135(12):3187-3189
pubmed: 26302070
Allergy. 1997 Mar;52(3):312-6
pubmed: 9140522
Int Arch Allergy Immunol. 2010;153(3):288-93
pubmed: 20484928
Eur Ann Allergy Clin Immunol. 2020 Mar 19;:
pubmed: 32191021
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1386-1388.e1
pubmed: 29175369
J Allergy Clin Immunol Pract. 2020 Jan;8(1):113-124
pubmed: 31374358
Drugs. 2014 Sep;74(14):1693-9
pubmed: 25217402
J Allergy Clin Immunol. 2001 Jun;107(6):1056-62
pubmed: 11398085
Eur Ann Allergy Clin Immunol. 2018 Jan;50(1):5-9
pubmed: 29350016
Allergy Asthma Clin Immunol. 2015 Jul 21;11(1):21
pubmed: 26195984
J Immunol Res. 2018 Nov 21;2018:5615109
pubmed: 30584542
Ann Allergy Asthma Immunol. 2012 May;108(5):337-341.e1
pubmed: 22541405
G Ital Dermatol Venereol. 2019 Aug;154(4):444-456
pubmed: 30717573
Harefuah. 2017 Jun;156(6):385-389
pubmed: 28661105
J Allergy Clin Immunol. 2012 May;129(5):1307-13
pubmed: 22336078
N Engl J Med. 2019 Oct 3;381(14):1321-1332
pubmed: 31577874
N Engl J Med. 1993 Jun 3;328(22):1599-604
pubmed: 7683772
Ann Allergy Asthma Immunol. 2014 May;112(5):419-25
pubmed: 24656924
World Allergy Organ J. 2019 Feb 23;12(2):100011
pubmed: 30937137
J Allergy Clin Immunol. 2018 Sep;142(3):876-882
pubmed: 29208545
J Allergy Clin Immunol. 2014 May;133(5):1270-7
pubmed: 24766875
Br J Dermatol. 2019 May;180(5):1077-1082
pubmed: 30560994
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):586-599
pubmed: 28916431
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1144-1151
pubmed: 29779967
Isr Med Assoc J. 2014 Aug;16(8):487-90
pubmed: 25269339
Int Arch Allergy Immunol. 2020;181(5):321-333
pubmed: 32224621
J Allergy Clin Immunol Pract. 2015 Jul-Aug;3(4):648
pubmed: 26164583
World Allergy Organ J. 2019 May 10;12(5):100033
pubmed: 31193160
Autoimmun Rev. 2017 Dec;16(12):1196-1208
pubmed: 29037900
Br J Dermatol. 2017 Oct;177(4):e96-e97
pubmed: 28129676
Eur J Dermatol. 2017 Feb 1;27(1):10-19
pubmed: 27882879
Allergy. 2017 Apr;72(4):519-533
pubmed: 27861988
Ann Dermatol. 2014 Apr;26(2):145-9
pubmed: 24882966
Allergy. 2018 Dec;73(12):2406-2408
pubmed: 30076605
J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1743-1745
pubmed: 28988786
Allergy. 2014 Jul;69(7):868-87
pubmed: 24785199
Clin Exp Allergy. 2019 May;49(5):655-662
pubmed: 30415478
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1108-1117
pubmed: 30033912
Allergy. 2019 Dec;74(12):2427-2436
pubmed: 31228881
J Invest Dermatol. 2015 Mar;135(3):925
pubmed: 25501032
World Allergy Organ J. 2018 Jul 4;11(1):14
pubmed: 29988758
Intern Med J. 2019 Apr;49(4):526-528
pubmed: 30957371
World Allergy Organ J. 2018 Nov 16;11(1):32
pubmed: 30464782